ESTRO 36 Abstract Book

632 / 1082

S616 ESTRO 36 2017
_______________________________________________________________________________________________
+/- 0.08) & (1.53+/- 0.46) and IMRT was (1.65 +/- 0.44) &
(1.51 +/- 0.26) in right and left breast.
Conclusion
Tomotherapy provided significant reduction in heart’s
dose volume and mean lung dose.
EP-1141 Acute and late toxicity of IORT during BCS
followed by whole breast radiotherapy (WBI).
B. Urbanski1, A. Roszak Andrzej1, K. Bratos1, P. Milecki2,
A. Karczewska-Dzionk3, M. Litoborski4, S. Adamczyk5
1 Greater Poland Cancer Centre, Radiotherapy and
Gynecological Oncology, Poznan, Poland
2 Greater Poland Cancer Centre, Radiotherapy Ward I,
Poznan, Poland
4 Candela, Candela, Warsaw, Poland
5 Intra Op, Intra Op, Sunnyvale, USA
Purpose/Objective:
The aim of the study was to report acute and late toxicity
of intraoperative radiotherapy (IORT) given as a boost
during breast conserving surgery (BCS) followed by
adjuvant whole breast radiotherapy (WBRT).Material and
Methods
Between 2008 and 2011 in 150 breast cancers patients
treated in Greater Poland Cancer Centre. Intraoperative
radiotherapy as a tumor bed boost was applied using
mobile electron accelerator Mobetron 1000 (IntraOp
Medical, Inc.). IORT boost (10 Gy) was followed by 50 Gy
whole-breast external beam radiotherapy (EBRT).
Chemotherapy, if indicated, was given before EBRT. The
observation period was 1,5-5,5 years.
The data was assessed by CTCAE ver. 3.0 scale 1 month
and 6 months after RT. The statistical analysis was
performed with Maentel-Haenszel test. Late toxicity was
analyzed with LENT-SOMA scale 1 year after RT.
Results
Tab 1. Acute toxicity data set.
There was only grade I and II acute toxicity reactions.
There was no statistical significance differences between
(Mantel-Haenszel test) percentage of patients with acute
reaction in 1 month and 6 months after RT.
Tab 2. Late toxicity data set.
The late toxicity occurred in 82 patients (55%). The main
side effect of treatment was fibrosis, which has occurred
in 60 patients (73.1%) from 82 in general with late
radiation induced reactions. There was grade I and II
predominance. Grade III occurred in 5 patients (skin
retraction).
Conclusion
Intraoperative radiotherapy is proved to be safe, well
tolerable and perspective treatment procedure in breast
cancer treatment.
EP-1142 EORTC QLQ C-30 scores evolution in stage I-III
breast cancer patients during sequential treatment
A. Vila1, J. Perez de Olaguer 1, P. Gallego1, G. Carrera1,
A. Pedro1
1Platón Hospital, Oncology and Radiation therapy,
Barcelona, Spain
Purpose or Objective
To analyse the quality of life in stage I-III breast cancer
patients under systemic treatment versus in adjuvant
radiotherapy respect a control group, to observe and to
assess priorities regarding quality of life
Material and Methods
Between May and July of 2014, n: 90 EORTC QLQ C-30
global tests were retrospectively observed in 48 women
divided in 3 groups: A) Sixteen breast cancer patients
under systemic treatment (following adjuvant
chemotherapy or hormonal treatment). B) Sixteen breast
cancer patients following radiotherapy were scored at the
beginning, during radiotherapy and when radiotherapy
courses just ended. C) Sixteen women, hospital workers,
without cancer control group, which two were finally
refused because they had symptoms of chronic fatigue
Results
Women mean ages were 63.5 years old (A), 60.5 years old
(B) and 41 years old in group C, respectively.
Among those 32 breast cancer patient (n: 76 tests), 6 (19%)
were submitted to mastectomy and 26 (81%) to
conservative surgery, with 5 of them that had been
treated with neo - adjuvant chemotherapy. Breast cancer
(TNM) stage was I, II or III in 50%, 37.5% and 12.5%,
respectively.
Asthenia was the main symptom in all cases being low in
control group. However, asthenia was considerable or
severe in the 56% of cases in the systemic treatment group
and 27.5% in radiotherapy group. Asthenia increases a 6%
just after radiotherapy. Apart of asthenia, by groups; A)
they showed weakness (87.5%) and anorexia (70%) in
relation with cytotoxic effects, and 50% in this group of
patients showed considerable to severe depression
feeling. B) Pain (50%), generally caused by the set-up
position and the skin effects of radiotherapy, and 31% of
this group of patients showed considerable to severe
depression feeling. C) Low degrees of Insomnia,
constipation and mild depression were also present in this
group.
It was found relationship between high degrees of fatigue
and females older than 45 years old, tumour poor
differentiation, advanced II-III stage, and hormonal
treatment when they were tested. In second term PS,
several skeleton bone or articular diseases. The presence
of mastectomy and thyroidal diseases were frequent in the
worst answer tests. Also depression status is determinant
in prognosis, but none common profile or clear
relationship between high degrees of fatigue and
biological factors as ki67, P-53, hormonal receptors,
perineural affection, C-her2neu/FISH, tumoral markers as
CA 15.3 were foundConclusion
1. Quality of live and treatment toxicities differed among
patients under systemic treatment or radiotherapy, since
the toxicity is cumulative. 2. Asthenia is the main
symptom in all cases. 3. The data of high depression
redraw the need of psychological and social cares. 4.
International organisms recommend applying probate
quality of life tests in every oncology department, if
possible
EP-1143 Hypofractionated vs conventionally
fractionated breast radiotherapy: Economic
consequences.
A.C. Ciafre1, J.M. Torices1, E. Jordá 1, D. Dualde1, R.
García1, E. Ferrer1
1Hospital Clinico Universitario, Oncologia Radioterapica,
Valencia, Spain
Purpose or Objective